CNBX Pharmaceuticals (CNBX) Stock Statistics & Valuation Metrics

CNBX Pharmaceuticals has a market cap or net worth of $27.75K. The enterprise value is ―.

CNBX Pharmaceuticals has 92,511,350 shares outstanding. The number of shares has decreased by -2.65% in one year.

CNBX Pharmaceuticals’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 10.88%.

The current PE Ratio of CNBX Pharmaceuticals is ―. CNBX Pharmaceuticals’s PEG ratio is 0.00170.

In the last 12 months, CNBX Pharmaceuticals had revenue of 0.00 and earned -313.98K in profits. Earnings per share was 0.00.

In the last 12 months, operating cash flow was -191.01K and capital expenditures 1.20K, giving a free cash flow of -191.01K billion.

CNBX Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

CNBX Pharmaceuticals upcoming earnings date is ―, ―.

CNBX Pharmaceuticals as a current ratio of <0.01, with Debt / Equity ratio of -52.82%

In the past 12 months, CNBX Pharmaceuticals has paid 0.00 in taxes.

CNBX Pharmaceuticals EV to EBITDA ratio is -0.11, with an EV/FCF ratio of -0.18.

CNBX Pharmaceuticals has $13.65K in cash and marketable securities with $1.34M in debt, giving a net cash position of -$1.33M billion.

Gross margin is 393.31%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for CNBX Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―